-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

Benzinga·10/30/2026 17:24:35
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $536 to $320.